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Abstract 
Acromesomelic dysplasia are a heterogeneous group of disorders with variable spectrum and 
severity of skeletal anomalies in the affected individuals. Acromesomelic dysplasia type 
Maroteaux (AMDM) is characterized by extreme shortening of the forelimbs and 
disproportionate short stature. Several homozygous inactivating mutations in NPR2 have been 
identified in different AMDM patients. We report five novel variants in affected individuals in 
four different families. These include two nonsense and three missense variants. This study 
broadens the genotypic spectrum of NPR2 mutations in individuals with AMDM and also 
describes the intra- and inter-familial phenotypic variability due to NPR2 variants. 
Keywords: Acromesomelic dysplasia; AMDM; NPR2; Skeletal dysplasia; short stature 
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Introduction 
Acromesomelic dysplasia are a heterogeneous group of autosomal recessively inherited 
disorders, categorized on the basis of their disease severity and the gene mutated in affected 
individuals. Disproportionate shortening of skeletal elements is the key feature of acromesomelic 
dysplasia which predominantly affects the forelimbs (forearms and legs) and distal segments 
(hands and feet) of the appendicular skeleton.  In Acromesomelic dysplasia type Maroteaux 
(OMIM#602875) the anomalies of the appendicular skeleton may be accompanied with changes 
in the axial skeleton, including wedging of the vertebrae. Affected individuals have normal 
intellect and have no extra-skeletal phenotypes. 
NPR2 (OMIM#602875) variants have been identified as the cause of AMDM (Bartels et al., 
2004). NPR2, located on chromosome 9, encodes natriuretic peptide receptor B (NPR-B) (Lowe 
et al., 1990), a receptor homodimer which is present in chondrocytes and is responsible for 
producing cyclic GMP after binding C-type natriuretic peptide (CNP). NPR-B (NPR2) is one of 
three natriuretic peptide receptors (NPR-A, NPR-B, NPR-C) (Potter et al., 2005) which interacts 
with natriuretic peptides and regulates different physiological process including endochondral 
ossification, cardiac development and blood pressure (Langenickel et al., 2006; Tamura et al., 
2004). NPR2 has four domains, an extracellular ligand binding domain, a transmembrane 
domain, an intracellular kinase homology domain (KHD) and a guanylyl cyclase (GC) domain at 
the C-terminal (Schulz, 2005).  
In the present study, we describe the phenotypic and genetic findings of three Pakistani and one 
Finnish family with multiple affected individuals exhibiting typical features of Acromesomelic 
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dysplasia type Maroteaux. We have identified five novel variants in NPR2 segregating with the 
disease phenotype in these families. 
Material and methods 
Samples 
The study was approved by the institutional review board of School of Biological Sciences, 
University of the Punjab, Lahore, Pakistan and Research Ethics Committee of Helsinki 
University Hospital, Finland.  Families MID-02, NAD-08 and NAD-09 were from Pakistan and 
were identified and recruited for study through personal contacts. Written informed consents 
were obtained from all participating individuals or from the parents for minor children.  Family 
FD-01 was followed at Children’s Hospital, Helsinki. Data were collected retrospectively from 
hospital records. 
Heights of the participants were measured and some individuals were photographed. Blood 
samples of all available individuals were obtained for extraction of genomic DNA. The DNA 
was isolated by a standard protocol involving sucrose lysis and salting out.  Radiographs of 
hands, feet and spine of affected individuals were obtained except for family MID-02 who did 
not consent to radiographic assessment. Amino‐terminal proCNP (NT‐proCNP) testing, a 
biomarker for AMDM  due to NPR2 variants, (Wang et al. 2016), could not be performed due to 
lack of testing facility. 
Mutational Screening 
For family MID-02, whole-exome sequencing was performed on DNA sample from individual 
IV: 3 using Agilent V4 enrichment kit (Agilent Technologies, Santa Clara, CA). 50× coverage of 
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paired-end reads were obtained on an Illumina Hi-Seq 2000 sequencer (Otogenetics, Norcross, 
GA). Reads were mapped to UCSC hg19 reference human genome (http://genome.ucsc.edu/). 
The annotation of variants was completed using wANNOVAR (http://wannovar.usc.edu/).  All 
heterozygous variants and variants with a minor allele frequency (MAF) equal to or greater than 
0.01 in public databases (dbSNP database, GnomAD, Exome Aggregation Consortium (ExAC), 
1000 Genomes and 6500 exon sequence project) were excluded. Exonic and splice site variants 
were considered for downstream analysis.  Agilevariant mapper 
(http://dna.leeds.ac.uk/agile/AgileGenotyper/) was used for identification of homozygous 
chromosomal intervals in the exome data. 
Genetic analysis for all members of family FD-01 was performed commercially (CTGT 
laboratory, USA) by targeted gene sequencing. Candidate gene screening was used for 
mutational analysis in families NAD-08 and NAD-09. Primers spanning all 22 exons and splice 
sites of NPR2 were designed  (sequences available upon request). PCR amplification with each 
primer set was carried out and followed by Sanger sequencing with BigDye Terminator v3.1 
cycle sequencing kit (Applied Biosystems). All variants were checked for segregation with the 
phenotype in the respective families by Sanger sequencing of the corresponding exons 
containing the mutation. The sequencing data were analyzed using Seq Scape software. The 
information for the identified variants was deposited in Leiden Open Variation Database 3.0- 
LOVD, (http://www.lovd.nl/3.0/home).  
The pathogenicity of identified variants was assessed using online prediction tools including 
Polyphen 2 (http:// http://genetics.bwh.harvard.edu/pph2/) MutationTaster 
(http://www.mutationtaster.org/), Mutation Assessor (http://mutationassessor.org/r3/) and 
M.CAP (http://bejerano.stanford.edu/mcap/). Alignments of orthologous NPR2 protein 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
6 
 
sequences were generated using (1) Clustal Omega after retrieving sequences from Ensembl (2) 
and (2) MUSCLE in Geneious after obtaining orthologues from NCBI’s Whole Genome Shotgun 
contig database via BLASTing (discontiguous megablast) a human reference sequence 
(Ensembl).   
Results 
Clinical Features 
Family MID-02 is comprised of four affected individuals (Supplementary Figure 1) with typical 
features of Acromesomelic Dysplasia, type Marotaeux including extremely short forearms and 
forelegs. One of the parents was of normal height, while the other was reported to have below 
average height. Family NAD-08 had five individuals with skeletal anomalies (Supplementary 
Figure 1). All affected individuals had typical features of AMDM with short stature, extreme 
shortening of forearms and forelegs, brachydactyly (Fig. 1a) and restricted movement of elbow 
(Table 1).  The heights of the obligate carriers I: 1 and: I: 2 were 167 cm (Z-score -1.2) and 155 
cm (Z-score-1.2) respectively, which are slightly below average normal heights.  
In family NAD-09 there are three affected individuals from three different consanguineous 
marriages (Supplementary Figure 1). Samples from only one affected individual, his parents and 
unaffected brother were available for genetic analysis. The affected individual presented with 
very short height and extreme shortening of forelimbs. He had brachydactyly of fingers and 
macrodactyly of toes. He has severe back pain for the last few years which is currently being 
treated. Both his parents had short heights, 162 cm (Z-score -3.2) (father) and 142 cm (Z-score -
2.0) (mother) who also had short hands (Table 1). 
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Family FD-01 included two daughters, born to healthy and unrelated Finnish parents 
(Supplementary Figure 1). Heights of parents were 172 cm (Z-score -0.7) (father) and 160 cm 
(Z-score -0.5) (mother). Both girls had significant short stature (Table 1).  
Radiographs of family NAD-08 (not shown), NAD-09 (Fig. 1b) and FD-01 (Fig. 1c) showed 
marked shortening of radius and ulna, and short fingers and toes, with premature fusion of the 
growth plates. Spinal radiographs, available for the older child in family FD-01 at 10 years, 
showed lack of widening of the interpedicular distance in the lumbar spine (Fig. 1c). 
Longitudinal data of heights was available for the two affected individuals in family FD-01.Their 
heights deviated from normal values during the first year and again during puberty (Fig. 1d).   
Genetic Analysis 
Analysis of whole-exome sequencing data revealed a missense variant c.872A>G; 
p.(Gln291Arg) (LOVD ID: 00179514) in NPR2 (NM_ 003995.3) which segregated with the 
disease phenotype in family MID-02 (Fig. 2a, Table 2).  This variant was absent from public 
databases including gnomAD (http://gnomad.broadinstitute.org/) as well as in ethnically matched 
200 control chromosomes.  The amino acid Gln291 is completely conserved among 133 species 
of mammals examined (Supplementary Figure 2) as well as birds but not in lower vertebrates 
which include lizard, frog and fish (Fig. 2b). 
 Analysis of sequencing data of family NAD-08 revealed a homozygous missense mutation 
c.368G>T; p.(Gly123Val) (LOVD ID: 00179511) in exon 1 of NPR2 (Table 2). The variant 
segregated with the phenotype as all affected individuals were homozygous and obligate carriers 
were heterozygous (Fig. 2c). The variant was predicted to be pathogenic or deleterious by 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
8 
 
various online tools (Table 2). The amino acid Gly123 is conserved among all species examined 
(Fig. 2d).  
In family NAD-09, a homozygous stop-gain mutation c.1185G>A; p.(Trp395Ter) (LOVD ID: 
00179513) was identified in exon 5 of NPR2 (Table 2).  The parents and the unaffected brother 
were heterozygous for the mutation (Fig. 2e). 
 In family FD-01 compound heterozygous variants in NPR2 at positions c.2965C>T; 
p.(Arg989Ter) and c.2966G>T; p.(Arg989Leu) (LOVD ID: 00179516) were identified in both 
affected individuals (Table 2, and data not shown). The c.2965C>T variant was inherited from 
the father while the c.2966G>T variant was inherited from the mother (Supplementary Figure 1). 
The residue Arg989 is conserved among all species examined (Fig. 2f).  
All five variants were absent from the public Human Gene Mutation Database 
(http://www.hgmd.cf.ac.uk/, accessed May, 2018) and also from recently published research. 
The p.(Gln291Arg), p.(Trp395Ter), p.(Arg989Ter), and p.(Arg989Leu) variants were absent in 
public databases whereas only one heterozygous allele for variant p.(Gly123Val) was present in 
ExAC database with an allele frequency of 0.000008239  (http://exac.broadinstitute.org/).  
Discussion 
Acromesomelic dysplasia type Maroteaux is characterized by short stature, extreme shortening 
of forearms and forelegs including shortening of hands and feet bones and also involvement of 
appendicular skeleton with broadening of vertebrae. The birth lengths of limbs may be normal 
and decreased growth becomes evident from the second year of life. Pathogenic variants in 
NPR2 cause skeletal dysplasia in patients with AMDM (Bartels et al., 2004). We identified five 
novel variants in NPR2 in unrelated affected individuals. The phenotypes of all affected 
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individuals were typical of AMDM. To date, homozygous or compound heterozygous mutations 
have been identified in AMDM patients of different ethnic origins. Heterozygous variants have 
been identified in individuals with idiopathic short stature (mutations with dominant-negative 
effect) (Olney et al., 2006; Vasques et al., 2013; Wang et al., 2015) or tall stature (gain-of-
function mutations) (Hannema et al., 2013; Miura et al., 2014; Miura et al., 2012).  In the present 
study, biallelic variants in NPR2 account for the phenotype of AMDM in the patients and mild 
short stature in the heterozygous carriers. Our finding that heterozygous carriers of variant 
p.(Trp395Ter) also have short stature (Table 1), indicates that loss-of-function NPR2 alleles can 
also result in idiopathic short stature in humans.  
NPR2 interacts with C-type natriuretic (CNP) peptide which acts in an autocrine or paracrine 
manner. CNP is highly expressed in the hypertrophic zone of growth plate and plays an 
important role in endochondral ossification and cartilage matrix synthesis (Nakao et al., 2015). 
The CNP/NPR2 interaction is thought to play an important role in the development of 
longitudinal growth of bones and any disruption in this signaling can lead to defective 
ossification of bones(Tamura et al., 2004). Several animal studies have provided evidence that 
homozygous or compound heterozygous variants in Npr2 can lead to AMDM in animal models 
(Sogawa et al., 2007; Tsuji and Kunieda, 2005).   
All reported variants in NPR2 are hypothesized to cause disease by either altering its ligand 
binding affinity or by diminishing  guanylyl cyclase activity (Wang et al., 2016). The 
p.(Gly123Val), p.(Gln291Arg), and p.(Trp395Ter) variants identified in the present study are 
located in the ligand binding domain (Fig. 2g). We hypothesize that these variants cause the 
disease by altering the binding of CNP to NPR2. The variants identified in family FD-01 
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p.(Arg989Leu) and p.(Arg989Ter) are located in guanylyl cyclase domain of NPR2 and likely 
cause the disease by diminishing the activity of NPR2 protein.   
The nonsense mutation identified in NAD-09 is located in exon 5 of NPR2 which has 22 exons 
in total. Therefore, it is likely to cause nonsense mediated decay of NPR2 mRNA and will 
probably result in absence of NPR2 in these patients. 
 The Glutamine 291 codon mutated in family MID-02 is conserved in all mammals examined but 
is not conserved in lizards, amphibians and fish. This could be due to the skeletal differences or 
epistatic effects among these classes. The retention of Gln291 in the 133 mammal species we 
examined suggests that natural selection has strictly maintained this residue for approximately 
160 million years, underscoring its probable functional importance in humans. The NPR2 
pathogenic missense variants p.(Thr297Met), p.(Tyr338Cys) and p.(Ala409Thr) previously 
reported in different AMDM individuals, also affect residues which are only conserved in 
mammals, though this fact was not stated in that study (Bartels et al., 2004). 
The affected individuals in families NAD-08 and NAD-09 had long faces as described in a few 
earlier studies (Khan et al., 2012; Srivastava et al., 2016). The affected individual in family 
NAD-09 has a severe backache complaint for the last two years. Spinal radiographs of one of the 
subjects in family FD-01 showed narrow spinal canal in the lumbar region indicating a risk for 
later development of spinal stenosis, which could be the cause of back pain also in the individual 
in NAD-09. The heterozygous carriers of the variants in all families had mild short stature. 
However, the heterozygous carriers in family NAD-09 with the nonsense allele were shorter (-
3.2 and -2.0 SD) as compared to those who were heterozygous for the missense variant in family 
MID-02 and NAD-08 (-1.2 and -1.2 SD). Moreover, the heterozygous variant carriers in family 
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NAD-09 had short hands. Disproportionate body, short stature and nonspecific skeletal 
anomalies have been previously reported in individuals with idiopathic short stature due to 
heterozygous variants in NPR2 (Vasques et al., 2013). A dominant negative effect of mutant 
alleles has been identified which impairs NPR2 in these individuals. Interestingly, for family 
NAD-09, haploinsufficiency also results in a mild phenotype in the carriers of the variants. 
The finding of three different variants of NPR2 identified in three unrelated families from 
Pakistan in our study depicts the allelic heterogeneity of AMDM contrary to the identification of 
c.2720C>T; p.(Thr907Met) pathogenic variant in five unrelated Pakistani families. This was 
shown to be due to a founder effect (Khan et al., 2012). Although these five families were from 
the province of Punjab (Khan et al., 2012) as were the three Pakistani families that we present in 
this work, it is possible that the members participating in the previous study were from adjacent 
villages or cities of Punjab, which would explain the different mutational spectrum in these 
studies. 
In conclusion we have identified five novel variants in NPR2 in four different families. The 
mutations cause disease phenotype in the respective families. Moreover, the NPR2 variant 
p.(Gln291Arg) is conserved only among mammals, which highlights the fact that some 
functional properties conferred by an amino acid to a protein may be important for proper 
biological function in mammals only.  
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Legends 
Figure 1. Clinical features of selected patients.  
 (a) Selected photos of Pakistani patients, their forearms/hands feet.  (b) Radiographs of one 
Pakistani patient (NAD-09, IV:4), showing shortening of radius and ulna and broadened 
metacarpals; short and broadened tibio-fibula; and stubby toes. (c) Radiographs and photos of the 
Finnish patient showing shortened and broadened metacarpals and toes. (d). Growth curves of 
individuals FD-01, II: 1 (left) and FD-01, II (right). (Colored figure can be observed in the online 
edition) 
 
Figure 2. NPR2 variants, conservation and protein structure  
(a) Partial chromatograms of DNA sequence of NPR2 of family MID-02. Arrow indicates the 
changed nucleotide. (b) Clustal Omega sequence alignment of NPR2 from diverse vertebrate 
species showing conservation of Glutamine at position 291 (c) Partial chromatograms of DNA 
sequence of NPR2 of family NAD-08. The variant nucleotide is indicated with an arrow. (d) 
Clustal Omega sequence alignment of NPR2 showing conservation of Glycine at position 123 (e) 
Partial chromatograms of NPR2 DNA sequence of family NAD-09. The variant nucleotide is 
indicated with an arrow. (f) Clustal Omega sequence alignment of NPR2 showing conservation 
of Arginine at position 989 among diverse orthologues. Arrows indicate the point of variant. (g) 
Schematic representation of NPR2 indicating position of variants identified in present study in 
NPR2. (Colored figure can be observed in the online edition) 
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Table 1. Phenotypes of individuals of AMDM families 
Family Individual Sex Age 
(years) 
Height 
(cm) 
SD Zygosity Clinical features 
MID-02 
c.872A>G 
IV:3 F 18 92.7 -10.2 Homozygous Markedly short forearms, short and broad 
fingers and toes, limited extension of elbows, 
motor milestones normal. 
IV:4 F 16 99 -9.7 Homozygous Markedly short forearms, short and broad 
fingers and toes, limited extension of elbows, 
motor milestones normal. 
IV:5 F 12 96.5 -7.3 Homozygous Markedly short forearms, short and broad 
fingers and toes, limited extension of elbows, 
motor milestones normal. 
NAD-08 
c.368G>T 
II:1 F 58 155 -1.2 Heterozygous Slightly short hands and feet. 
II:2 M 65 167.5 -1.2 Heterozygous Slightly short hands and feet. 
III:3 M 20 119 -8.0 Homozygous Markedly short forearms, short and broad 
fingers and toes and broad forehead and face, 
limited extension of elbows, motor milestones 
normal. 
III:4 M 27 122 -7.5 Homozygous Markedly short forearms, short and broad 
fingers and toes and broad forehead and face, 
limited extension of elbows, motor milestones 
normal. 
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III:6 F 30 116 -7.2 Homozygous Markedly short forearms, short and broad 
fingers and toes and broad forehead and face, 
limited extension of elbows, motor milestones 
normal. 
III:8 F 23 167.6 +0.6 Wild type Normal hands and feet. 
V:5 M 25 NA NA Homozygous Markedly short forearms, short and broad 
fingers and toes broad forehead and face, 
limited extension of elbows, motor milestones 
normal. 
NAD-09 
c.1185G>A 
III:1 F 55 142 -3.2 Heterozygous Short hands and feet. 
III:2 M 59 162 -2.0 Heterozygous Short hands and feet. 
IV:2 M 28 167 -1.3 Heterozygous Short hands and feet. 
IV:3 M 25 109 -9.3 Homozygous Markedly short forearms, short and broad 
fingers and toes, limited extension of elbows, 
motor milestones normal. Severe pain in back 
for last few years. 
FD-01 
c.2965C>T 
c.2966G>T 
I:1 F NA 160 -0.5 Heterozygous No skeletal phenotype. 
I:2 M NA 172 -0.7 Heterozygous No skeletal phenotype. 
II:1 F 17 119.2 -8.2 Compound 
Heterozygous 
Broad forehead, low nasal bridge, markedly 
short forearms short and broad fingers and 
toes, limited extension of elbows, motor 
milestones normal. 
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cm: centimeters, F: female, M: male.NA, not available 
 
II:2 F 4 76.3 -6.9 Compound 
Heterozygous 
Broad forehead, low nasal bridge, markedly 
short forearms short and broad fingers and 
toes, limited extension of elbows, motor 
milestones normal. 
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Table 2. NPR2 variants identified in the present study 
Family Chr. 
Position* 
cDNA 
change** 
Amino Acid 
change 
M-CAP Mutation 
Assessor 
Polyphen 2 
Score 
/prediction 
Mutation Taster 
NAD-08 9:35,792,773 c.368G>T p.(Gly123Val) 0.451 Medium 
impact 
0.735/ 
Possibly 
damaging 
Disease causing 
NAD-09 9:35,800,447 c.1185G>A 
 
p.(Trp395Ter) NA NA NA Disease causing 
MID-02 9:35,794,099 c.872A>G p.(Gln291Arg) 0.035 Neutral 0.084/Neutral Disease causing 
FD-01 9: 35,808,829 c.2965C>T p.(Arg989Ter) NA NA NA Disease causing 
 9:35,808,830 c.2966G>T p.(Arg989Leu) 0.554 High 1.0/ Probably 
damaging 
Disease causing 
*Positions with reference to human genome build GRChg19/37 
**cDNA change is with respect to transcript: NM_003995.3 
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Highlights 
• We describe five novel variants in NPR2  
• Biallelic NPR2 variants cause AMDM in four families 
• We show that carriers of loss-of-function variants also had short stature 
 
